How should atrial fibrillation be managed regarding rate control, rhythm control, and stroke prevention?
Atrial fibrillation management centers on three pillars: stroke prevention using CHA2DS2-VASc scoring to guide anticoagulation, rate control targeting <110 bpm at rest for most patients, and rhythm control consideration for symptomatic patients. Direct oral anticoagulants are preferred over warfarin for non-valvular AF. Catheter ablation is increasingly considered early in the disease course.
Educational summary; not medical advice. Consult local guidelines and clinician judgment.
Stroke Prevention
CHA2DS2-VASc score guides anticoagulation decisions. Scores ≥2 in men or ≥3 in women indicate clear anticoagulation benefit. DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) are preferred over warfarin due to improved safety profile and fixed dosing. Warfarin remains appropriate for mechanical valves or moderate-severe mitral stenosis.
Rate versus Rhythm Control
Rate control is reasonable for many patients, particularly asymptomatic elderly. Lenient rate control (<110 bpm resting) is non-inferior to strict control for most outcomes. Rhythm control with antiarrhythmics or ablation is preferred for symptomatic patients, younger individuals, and those with heart failure where AF contributes to decompensation.
Catheter Ablation Considerations
Pulmonary vein isolation via catheter ablation is effective for paroxysmal and persistent AF. CASTLE-AF and CABANA trials support ablation benefit in heart failure patients. Early rhythm control strategy (EAST-AFNET 4) shows cardiovascular outcome benefits. Ablation should be discussed with symptomatic patients after failed or intolerant of antiarrhythmic therapy.
Points of Disagreement
Optimal patient selection for early ablation and role of left atrial appendage closure in anticoagulation-eligible patients remain evolving areas.
Multi-Guideline Agreement: High (91%)
Consensus Models: Gemini 3, Gemini 3 Pro, Sonnet 4.5, GPT 5.2
External Auditors: Grok 4, Opus 4.5
Last reconciled: December 31, 2025 | Version: 1.0